drugset / Trial / NCT00004929
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Phase 1
Completed
15 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
Timeline
- Start
- 1999-09
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MUC-2-KLH vaccine | Vaccine | — | — |
| Background | QS-21 | Other / unclassified | — | Subcutaneous |